P2RY12 and coronary artery disorder: A recent clinical guideline recommends that vascular-dose rivaroxaban or a P2Y12 inhibitor in addition to aspirin should be considered in CAD patients who are at moderate-to-high risk of ischemic events and low risk of major bleeding [4].